ArticleInfection and immunity2014
Protective immunity against recurrent Staphylococcus aureus skin infection requires antibody and interleukin-17A.
Article in Infection and immunity, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
83 citing papers in PubMed, 108 citations in OpenAlex.
- Role and plasticity of Th1 and Th17 responses in immunity toHuman vaccines & immunotherapeutics · 2019Trial
- Impact of Staphylococcus aureus USA300 Colonization and Skin Infections on Systemic Immune Responses in Humans.Journal of immunology (Baltimore, Md. : 1950) · 2016Trial
- Single-Cell Profiling Identifies Skin-Resident Memory CD4European journal of immunology · 2026Article
- The dynamic interplay betweenFrontiers in cellular and infection microbiology · 2026Review
- A comprehensive review of pathology and treatment of staphylococcus aureus osteomyelitis.Clinical and experimental medicine · 2025Review
- CD4+ T cell-innate immune crosstalk is critical during Staphylococcus aureus craniotomy infection.JCI insight · 2025Article
- Early cytokine signatures and clinical phenotypes discriminate persistent from resolving MRSA bacteremia.BMC infectious diseases · 2025Article
- A potential XGBoost Diagnostic Score forFrontiers in immunology · 2025Article
- Toxin-neutralizing Abs are associated with improved T cell function following recovery from Staphylococcus aureus infection.JCI insight · 2024Article
- Article
- Regulatory T cells control Staphylococcus aureus and disease severity of cutaneous leishmaniasis.The Journal of experimental medicine · 2023Article
- The Controversial Effect of Antibiotics on Methicillin-SensitiveInternational journal of molecular sciences · 2023Article
- Staphylococcus xylosus and Staphylococcus aureus as commensals and pathogens on murine skin.Laboratory animal research · 2023Review
- Myeloid-derived suppressor cells impair CD4+ T cell responses during chronic Staphylococcus aureus infection via lactate metabolism.Cellular and molecular life sciences : CMLS · 2023Article
- Clinical Impact ofAntibiotics (Basel, Switzerland) · 2023Review
- Toxin expression during Staphylococcus aureus infection imprints host immunity to inhibit vaccine efficacy.NPJ vaccines · 2023Article
- Cross-Protection against AcuteVaccines · 2023Article
- Article
- Toward Optimization of a Rabbit Model of Staphylococcus aureus (USA300) Skin and Soft Tissue Infection.Microbiology spectrum · 2022Article
- Antibiotic Treatment of Staphylococcus aureus Infection Inhibits the Development of Protective Immunity.Antimicrobial agents and chemotherapy · 2022Article
23 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Although many microbial infections elicit an adaptive immune response that can protect against reinfection, it is generally thought that Staphylococcus aureus infections fail to generate protective immunity despite detectable T and B cell responses. No vaccine is yet proven to prevent S. aureus infections in humans, and efforts to develop one have been hampered by a lack of animal models in which protective immunity occurs. Our results describe a novel mouse model of protective immunity against recurrent infection, in which S. aureus skin and soft tissue infection (SSTI) strongly protected against secondary SSTI in BALB/c mice but much less so in C57BL/6 mice. This protection was dependent on antibody, because adoptive transfer of immune BALB/c serum or purified antibody into either BALB/c or C57BL/6 mice resulted in smaller skin lesions. We also identified an antibody-independent mechanism, because B cell-deficient mice were partially protected against secondary S. aureus SSTI and adoptive transfer of T cells from immune BALB/c mice resulted in smaller lesions upon primary infection. Furthermore, neutralization of interleukin-17A (IL-17A) abolished T cell-mediated protection in BALB/c mice, whereas neutralization of gamma interferon (IFN-γ) enhanced protection in C57BL/6 mice. Therefore, protective immunity against recurrent S. aureus SSTI was advanced by antibody and the Th17/IL-17A pathway and prevented by the Th1/IFN-γ pathway, suggesting that targeting both cell-mediated and humoral immunity might optimally protect against secondary S. aureus SSTI. These findings also highlight the importance of the mouse genetic background in the development of protective immunity against S. aureus SSTI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.